Search research articles
Contact Us
Filters
Showing results (1-10 of 12) with videos related to
Page
of 2
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 25, 2014
Reply to the letter to the editor 'treating breast cancer with trabectedin: a new arsenal' by L. Malik
S Delaloge, M Cullell-Young
Drug News & Perspectives
|
July 22, 2005
Chronicles in drug discovery
V Khurdayan, M Cullell-Young
Journal of Leukocyte Biology
|
April 17, 1998
Transcription factors that regulate monocyte/macrophage differentiation
A F Valledor, F E Borràs, M Cullell-Young, et al.
Immunogenetics
|
May 11, 2001
From transcription to cell surface expression, the induction of MHC class II I-A alpha by interferon-gamma in macrophages is regulated at different levels
M Cullell-Young, M Barrachina, C López-López, et al.
ESMO Open
|
December 1, 2022
Antitumor activity of lurbinectedin in combination with oral capecitabine in patients with metastatic breast cancer
A H Awada, V Boni, V Moreno, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 3, 2014
Activity of trabectedin in germline BRCA1/2-mutated metastatic breast cancer: results of an international first-in-class phase II study
S Delaloge, R Wolp-Diniz, T Byrski, et al.
Cancer Chemotherapy and Pharmacology
|
August 29, 2012
A phase I and pharmacokinetic study of elisidepsin (PM02734) in patients with advanced solid tumors
R Salazar, R J Jones, A Oaknin, et al.
Cancer Chemotherapy and Pharmacology
|
March 5, 2013
A phase I pharmacokinetic study of PM00104 (Zalypsis) administered as a 24-h intravenous infusion every 3 weeks in patients with advanced solid tumors
J Capdevila, S Clive, E Casado, et al.
British Journal of Cancer
|
August 31, 2013
Phase I-II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma
R Plummer, P Lorigan, E Brown, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 30, 2017
Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study
E Calvo, V Moreno, M Flynn, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 12) with videos related to
Sort By:
Page
of 2
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 25, 2014
Reply to the letter to the editor 'treating breast cancer with trabectedin: a new arsenal' by L. Malik
S Delaloge, M Cullell-Young
Drug News & Perspectives
|
July 22, 2005
Chronicles in drug discovery
V Khurdayan, M Cullell-Young
Journal of Leukocyte Biology
|
April 17, 1998
Transcription factors that regulate monocyte/macrophage differentiation
A F Valledor, F E Borràs, M Cullell-Young, et al.
Immunogenetics
|
May 11, 2001
From transcription to cell surface expression, the induction of MHC class II I-A alpha by interferon-gamma in macrophages is regulated at different levels
M Cullell-Young, M Barrachina, C López-López, et al.
ESMO Open
|
December 1, 2022
Antitumor activity of lurbinectedin in combination with oral capecitabine in patients with metastatic breast cancer
A H Awada, V Boni, V Moreno, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 3, 2014
Activity of trabectedin in germline BRCA1/2-mutated metastatic breast cancer: results of an international first-in-class phase II study
S Delaloge, R Wolp-Diniz, T Byrski, et al.
Cancer Chemotherapy and Pharmacology
|
August 29, 2012
A phase I and pharmacokinetic study of elisidepsin (PM02734) in patients with advanced solid tumors
R Salazar, R J Jones, A Oaknin, et al.
Cancer Chemotherapy and Pharmacology
|
March 5, 2013
A phase I pharmacokinetic study of PM00104 (Zalypsis) administered as a 24-h intravenous infusion every 3 weeks in patients with advanced solid tumors
J Capdevila, S Clive, E Casado, et al.
British Journal of Cancer
|
August 31, 2013
Phase I-II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma
R Plummer, P Lorigan, E Brown, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 30, 2017
Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study
E Calvo, V Moreno, M Flynn, et al.
Page
of 2